In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical, a leading musculoskeletal solutions company, has announced its acquisition of Nevro Corp, a global medical ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...

Globus Medical (GMED), a musculoskeletal solutions company, Thursday agreed to acquire Nevro Corp. (NVRO), a medical device company, ...

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. to Globus Medical for $5.85 per share is fair to Nevro shareholders. Halper Sadeh encourages Nevro ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...